Angiotensin II receptor blockers (ARBs) represent a new class of effective and well tolerated orally active antihypertensive agents. Recent clinical trials have shown the added benefits of ARBs in hypertensive patients (reduction in left ventricular hypertrophy, improvement in diastolic function, decrease in ventricular arrhythmias, reduction in microalbuminuria, and improvement in renal function), and cardioprotective effect in patients with heart failure. Several large long-term studies are in progress to assess the beneficial effects of ARBs on cardiac hypertrophy, renal function, and cardiovascular and cerebrovascular morbidity and mortality in hypertensive patients with or without diabetes mellitus, and the value of these drugs in patients with heart disease and diabetic nephropathy.
Introduction
Angiotensin II receptor blockers (ARBs) represent a new class of effective and well tolerated orally active antihypertensive drugs [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] that inhibit the renin-angiotensin system by selectively blocking the AT 1 subtype of angiotensin II receptor. 1, 16, 17 A number of studies have demonstrated the efficacy of ARBs (used as monotherapeutic agents or in combination with other antihypertensive drugs) in the treatment of hypertension. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Initial studies indicate that ARBs, either alone or in combination with angiotensin-converting enzyme (ACE) inhibitors, are also useful in the management of heart failure. [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] Several large, long-term studies are in progress (Table 1) to assess the beneficial effects of ARBs on cardiac hypertrophy, renal function, and cardiovascular and cerebrovascular morbidity and mortality in hypertensive patients with or without diabetes mellitus, and the value of these drugs in patients with heart failure, acute myocardial infarction, and diabetic nephropathy.
Angiotensin receptor blockers as antihypertensive drugs
As antihypertensive agents, the ARBs are as effective as ACE inhibitors, thiazide diuretics, betablockers or calcium channel blockers, often with a better tolerability profile. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 21, 25, 29, 35, 43, 60 The ARBs are effective and relatively safe in the elderly hypertensives, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 42, 52, 63 and in patients with isolated systolic hypertension. 76 The antihypertensive efficacy of ARBs is enhanced when combined with diuretics, ACE inhibitors, calcium channel blockers, betablockers, or alpha-blockers. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 37, 52, 54, 55, 57 In combination with other classes of antihypertensive drugs, the ARBs are also efficacious in the treatment of JNC-VI Stage III (severe) hypertension. [77] [78] [79] [80] In general, the blood pressure lowering efficacy of ARB monotherapy is lower in black than in white hypertensives. 14, 15 However, addition of a diuretic to the therapeutic regimen abolishes the ethnic difference in blood pressure control. 14, 15, 79 
Advantages of angiotensin receptor blocker therapy in hypertension
Most of the ARBs control blood pressure for 24 h after once daily dosing. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 19, 21, 24, 25, [31] [32] [33] [36] [37] [38] [39] [40] 42, 44, 47, 50, 54, 56, [58] [59] [60] 62 Sustained efficacy has been shown with long-term therapy with ARBs, with no tachyphylaxis. [36] [37] [38] 42, 47, 48, 50 Age or gender have no The ARBs do not alter the circadian rhythm of blood pressure. 24, 31, 34, 40, 53, 62 Therapy with the ARBs does not cause first dose (excessive) hypotension or significant orthostatic hypotension. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 27, 49, 50, 59, 60 Cessation of treatment with ARBs causes no rebound hypertension. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 59 ARB therapy does not have any effect on heart rate and cardiac output or electrocardiographic data. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 19, 24, 34, 38, 39, 49, 50, 52, 58, 59 The ARBs do not impair cerebrovascular regulation, and may even improve cognitive function. Treatment with the ARBs does not result in clinically significant alterations in laboratory measurements of serum chemistry, haematology and urinalysis. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 19, 23, 39, 44, 50, 59, 62, 81 The ARBs do not impair glucose or lipid metabolism. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 19, [81] [82] [83] These drugs have no adverse effect on renal function. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 36, 39, 45, [84] [85] [86] [87] [88] [89] As a result of favourable safety profile, discontinuation rate with ARBs is low. In a study, it was shown that ARBs had the highest 1-year compliance rate among five major classes of antihypertensive drugs. 90 The benefits of ARB therapy of hypertension go beyond the reduction in blood pressure. The additional advantages of ARB therapy include: (1) reduction in left ventricular hypertrophy; 5, 22, 48, [91] [92] [93] [94] [95] (2) improvement in diastolic function; 96 36, 39, 45, [84] [85] [86] [87] [88] [89] except in patients with severe congestive heart failure or renal artery stenosis; (9) increase in insulin sensitivity; 102, 103 and (10) decrease in serum uric acid levels (by only losartan); [104] [105] [106] hyperuricaemia is associated with increased risk for stroke and heart attack in hypertensive patients.
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Commercially available angiotensin receptor blockers
After the introduction of the prototype drug, losartan, six more ARBs were approved for treatment of hypertension (Table 2) ; of these, tasosartan (Verdia) was withdrawn by the pharmaceutical company due to liver enzyme elevation. The available ARBs and their combinations (with hydrochlorothiazide) are Tasosartan (Verdia, ANA-756; WAY-ANA-756) was approved, but has been withdrawn due to adverse effects. Table 3 . At least 28 compounds are currently under investigation as potential ARBs (Table 4 ).
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The structures of angiotensin receptor blockers
The ARBs are non-peptide compounds with varied structures (Figure 1 ). There are some structural similarities among the ARBs: (a) candesartan, irbesartan, losartan, and valsartan have a common tetrazolobiphenyl structure; (b) candesartan and telmisartan have a common benzimidazole group; (c) with the exception of irbesartan, all active ARBs have a free carboxylic acid group. The structure of eprosartan is distinct from other ARBs.
The variation in the molecular structure of the ARBs results in differences in lipid solubility, binding affinity to AT 1 receptor (giving rise to differences in potency), and pharmacokinetic profile (rate and extent of absorption, distribution, oral bioavailability, effect of food on absorption, protein binding, half-life (t . ), biotransformation and systemic elimination) of the ARBs. These differences result in variations in the time of onset, duration of action, and efficacy of the individual ARBs.
Mechanism of blood pressure lowering action of angiotensin receptor blockers
The ARBs interfere with the renin-angiotensinaldosterone system by selectively blocking the binding of angiotensin II to its receptor subtype 1 (AT 1 ), 1, 16, 17 causing an insurmountable inhibition, thereby inhibiting the main physiological effects of angiotensin II. The blockade of angiotensin receptor AT 1 results in relaxation of smooth muscles, increase in salt and water excretion, reduction in plasma volume, and decrease in cellular hypertrophy. The antihypertensive effect of ARBs is mainly due to the reduction in peripheral vascular resistance.
Doses and potencies of angiotensin receptor blockers used in the treatment of hypertension
The ARBs vary in potency and duration of action. The recommended starting and maintenance dosages of these drugs for the treatment of high blood pressure are given in Table 5 . Lower initial doses are recommended in volume-and/or salt-depleted patients, and in patients with severe renal or hepatic disease for some ARBs.
The antihypertensive potency of the ARBs, based upon the starting dose in milligrams follows the sequence:
If the dose is expressed in millimoles, the potency order follows the sequence:
Although, most of the ARBs control blood pressure for 24 h after single daily doses, some patients may require twice daily dosing. Often, a diuretic may be added for increased efficacy; combination with drugs from other classes of antihypertensive agents also increase the efficacy of ARBs in controlling blood pressure (see above).
Pharmacodynamic characteristics of angiotensin receptor blockers
Candesartan cilexetil is a prodrug which is bioactivated in the body to candesartan.
14,15 A dose-depen- dent (blood pressure lowering) response has been observed for 4 -32 mg dose. 5, 12, 14, 15, 30, 49 Maximum antihypertensive effect occurs at 4 -6 h after an oral dose.
14,53 A trough plasma level-response relationship is found after repeated dosing, irrespective of age, weight, or gender of the patient. 12, 14 The trough/peak ratios of blood pressure are in the range of 0.7-1.0. 12, 30, 49, 62 The antihypertensive effect is well maintained for 24 h after 8-16 mg daily dose of candesartan cilexetil; 12, 14, 15, 20, 31, 53, 62 peak efficacy of antihypertensive effect is reached in 4 -6 weeks of daily dosing. 12, 14, 15 The basic structure of eprosartan is different from other ARBs (Figure 1 ). The drug does not require metabolic activation. 11, 56 Maximum blood pressure lowering effect occurs in 4 -6 h after the oral dose; 11 blood pressure may not be controlled for the full 24 h with once daily dosing. Eprosartan has no doseresponse relationship in the therapeutic dose range. 11 Peak efficacy of blood pressure lowering effect is reached in 4 -6 weeks.
Irbesartan does not require metabolic activation. 6, 10, 14, 15, 27 The drug exhibits nearly linear dose-response (blood pressure lowering) relationship for 50-300 mg dose. 6, 10, 23, 27, 32, 46 After oral dosing, maximum blood pressure lowering effect occurs at 3-6 h. 6, 14, 15 Peak efficacy of blood pressure lowering effect is reached in 4 -8 weeks. 6, 10, 14, 15 Irbesartan is effective in hypertensive patients, irrespective of age or gender. 14, 15 Long-term blood pressure control can be achieved (in many patients) with monotherapy, since trough/peak ratio of blood pressure is in the range of 0.7-1.0. 6, 14, 15, 27, 32 There is no difference in the efficacy of irbesartan between the morning dose and the evening dose.
Most of the antihypertensive action and the long duration of action of losartan is due to its active metabolite EXP3174, which is 10-40 times more potent than losartan. 2, 3, 9, 14, 15 The time for maximum effect (4-6 h) coincides with the time for peak plasma level (T max ) of the metabolite. 2 Although, dose-response relationship is observed for the 40-120 mg dose of losartan or plasma level-response relationship for the metabolite in blocking the pressor effect of exogenous angiotensin II in normotensive subjects, 108 no such relationship exists for the blood pressure lowering effect in hypertensive patients. 14, 15 The minimum dose of losartan to produce significant day-long blood pressure control in hypertensive patients is 50 mg; larger doses are no more efficacious. 3, 26 A daily dose of 100 mg of losartan may have a slightly higher response rate or longer duration of action. 59 Peak efficacy of blood pressure lowering effect is reached in 3-6 weeks. 4, 14, 15 The antihypertensive response to losartan is independent of age or gender. 14, 15 In some patients once daily dosing may not be sufficient to control blood pressure, although, the reported trough/peak ratio of blood pressure is in the range of 0.5-0.9.
Telmisartan is inherently active. 13, 15 The blood pressure lowering effect of the drug is related to the dose (20-80 mg). 15, 58 However, doubling of dose (from 40 mg to 80 mg) does not result in additional blood pressure reduction. 60 Telmisartan has a rapid onset of action (0.5-1.0 h), 13, 15 and maximum blood pressure effect occurs at 4 -6 h after the oral dose. 13, 15 Once daily doses of 40-80 mg provide 24-h blood pressure control. 13, 15, 40, 52, 60 The trough/peak ratio of blood pressure is in the range of 0.7-1.0, 15 although, plasma trough/peak level ratio is 0.1-0.25. Peak efficacy of blood pressure lowering effect is reached in 1-4 weeks. 15 The antihypertensive effect of telmisartan is unaffected by the age or gender of the patient. 15 Valsartan does not require metabolic activation. 8, 14, 15 The trough/peak ratio of blood pressure is in the range of 0.6-0.7. 15 Once daily dosing of valsartan is usually sufficient to control blood pressure for 24 h. 14, 15, 25 The peak efficacy of blood pressure lowering effect is reached in 4 -6 weeks. 14, 15 Maximum efficacy of valsartan is achieved at 80 mg dose, although, 160 mg dose may have a higher overall response rate. 59 
Adverse effects of angiotensin receptor blockers
The ARBs have a low incidence of adverse effects, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] 42, 44, [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] 62, 63, [76] [77] [78] [79] [80] [81] 88, 109, 110 even in the elderly. 29, 42, 52, 63 The adverse effect profile is often similar to that of placebo. Some of the adverse effects include, headache, dizziness, non-specific pain, upper respiratory tract infection, viral infection, asthenia/fatigue, sinusitis, and diarrhoea.
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Journal of Human Hypertension side effects are not dose related. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] First dose hypotension is uncommon (except in salt-and/or volume-depleted patients). Cough, the main adverse effect of ACE inhibitors, 111 occurs much less frequently with ARB therapy, and angioneurotic oedema is relatively rare.
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Pharmacokinetics and metabolism of angiotensin receptor blockers
Candesartan cilexetil: Candesartan cilexetil, an inactive racemic prodrug, is rapidly and completely metabolised (by ester hydrolysis) in the gastrointestinal tract to the active achiral candesartan. 12, 14, 15 The absolute bioavailability of candesartan (Table  6a ) is about 15%. 14, 15, 109 Food with high fat content does not have any effect on its absorption or bioavailability.
14,15 Plasma levels of candesartan are proportional to the dose and peak at 2-5 h after the dose of candesartan cilexetil. 12, 14, 109 Candesartan is highly bound to plasma proteins (Ͼ99%). 14, 15 The apparent volume of distribution (Vd) of candesartan is quite small (9 L). 14, 15 Total plasma clearance (Cl T ) of candesartan is 26 mL/min, and its plasma elimination t . is approximately 9 h (range = 6-13 h). 12, 14, 15, 109, 117 The dose-pharmacokinetic relationship is linear for candesartan cilexetil for doses of 8-32 mg. 12, 14, 15 A nonsignificant accumulation (up to 20%) is observed (Table 6b) after  repeated dosing. 14,15,109 The drug does not distribute into red blood cells to an appreciable extent. 14, 15 Candesartan is not metabolised by the cytochrome P450 system, but is de-ethylated and glucuronidated to a small extent. 14, 15, 117 After an oral dose, candesartan is excreted (Table 7) mainly unchanged in faeces (via bile) and in urine (26-33%);
14,15,20 a minor inactive metabolite formed by de-ethylation is also excreted.
14,15
Eprosartan: After oral administration, eprosartan is fairly rapidly absorbed (T max = 1-3 h), but its bioavailability (Table 6a) is low (about 13%) due to incomplete absorption. 11, 118, 119 High fat food increases bioavailability [increase in peak plasma levels (C max ) by 80% and in the area under the plasma level-time curve (AUC) by 55%], but slows its absorption, possibly by prolonging residence time in the gastrointestinal tract; 11,118,120,121 these changes do not require dosage adjustment in the fasting state.
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The dose-C max and dose-AUC relationships for single doses in the range of 100-800 mg of eprosartan, are less than proportional due to saturation of absorption. 122 Eprosartan is highly bound to plasma proteins (98%), 11, 120, 123 and has a small steady-state Vd (13 L). 11, 118 It has a low systemic Cl T (Table 6b ; 130 mL/min). 89 The terminal t . of orally administered eprosartan is 5-9 h (about 2 h after intravenous administration).
11,118-120 The drug does not accumulate after repeated dosing. 124 Eprosartan is metabolised to a small extent, by enzymes other than cytochrome P450. 125 Most of the oral dose is excreted unchanged in the faeces (Table  7) . 11, 118, 120, 125 Irbesartan: After an oral dose, irbesartan is rapidly and completely absorbed.
6,14,15,32,41,126 The absolute bioavailability is in the range of 60-80% (Table  6a) . 14, 15, 32, 126, 127 Food does not influence neither the absorption nor bioavailability of the drug. 6, 14, 15, 32, 126, 127 Peak plasma levels of irbesartan are achieved at 1.3-3 h after oral dosing. 6, 32, 41, 61, 110, [126] [127] [128] [129] Irbesartan displays linear doserelated pharmacokinetics over the dose range of 50-600 mg. 6, 14, 15, 110 The drug is 90% bound, mainly to albumin (binding to alpha 1-acid glycoprotein = 22%). 6, 14, 15 Steady-state plasma levels are reached in 3 days after daily dosing, and no clinically important accumulation (Ͻ20%) occurs (Table  6b) . 6, 14, 15, 110, 129 The Vd of irbesartan is between 53 L and 93 L, and it has a Cl T of 157-177 mL/min (Table  6b) . 14, 15, 126 Irbesartan has a long plasma elimination t . (11-18 h) . 6, 14, 15, 32, 41, 61, 110, [126] [127] [128] The hepatic extraction ratio of irbesartan is low (0.2), 126 and the drug is partially metabolised (6% of the dose) by oxidation (by cytochrome CYP2C9) and glucuronidation to form eight inactive metabolites. 14, 15, 130 The metabolites account for only 9% of the circulating drug, 5-10% in urine and 6% in faeces. 14, 15, 131 Most of the administered dose (80%) is excreted in faeces via bile (Table 7) , and the remainder in urine. 6, 14, 15, 126 Losartan: Losartan is pharmacologically active, but its major metabolite EXP3174 (10-40 times more potent than losartan) is responsible for most of its pharmacological activity (see above), 2, 3, 14, 15, 133 and long duration of action. 2, 3, 133 After oral administration, losartan is rapidly absorbed, and undergoes substantial first-pass metabolism by cytochrome P450 enzymes. 14, 15, 135 The T max (Table 6a ) of losartan and EXP3174 are 1-1.3 h and 3-6 h, respectively.
14,15,132-134 Systemic bioavailability of losartan is 33% (range = 29-43%). [132] [133] [134] About 14% of an oral or intravenous dose of losartan is converted to EXP3174. 14, 15, 133, 134 The C max and AUC of losartan and EXP3174 are linearly related to the dose of losartan (25-200 mg). 18 The C max AUC of EXP3174 is two to four times higher than for losartan. 18, [132] [133] [134] Food delays the absorption of losartan and lowers its C max , but the AUC of losartan or EXP3174 are not significantly altered. 14, 15, 132 Losartan and EXP3174 are highly bound (Table 6a ) to plasma proteins (98.7% and 99.8%, respectively), primarily to albumin. 14, 15, 135 The apparent Vd of losartan and EXP3174 is in the range of 28-47 L and 10-12 L, respectively. 14, 15, 133, 134 The Cl T of losartan and EXP3174 is about 600 mL/min and 50 mL/min, respectively (Table 6b) . 14, 15, 133, 134 Plasma elimination t . of losartan and EXP3174 ranges from 1-3 h and 5-10 h, respectively. 14, 15, 133, 134, [136] [137] [138] No significant accumulation of losartan or EXP3174 occurs after repeated dosing. 133 Losartan is oxidized by cytochromes CYP2C9 and CYP3A4 to the active carboxylic acid metabolite EXP3174. 14, 15, 136, 138, 139 In addition, hydroxylation and glucuronidation result in several metabolites which are much less active than losartan. 14, 15, 139 Faecal excretion accounts for about 65% of the oral dose ( Table 7) and 50% of the intravenous dose of losartan; the remainder is excreted in urine. 14, 15 Biliary route contributes significantly to the total elimination of losartan and EXP3174. In the urine, 4 -5% of the dose is present as losartan and 6-8% as EXP3174. 14, 15, [133] [134] Telmisartan: The drug is rapidly absorbed (T max = 0.5-1 h) 13, 15, 58, 140 following oral administration.
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Telmisartan has an absolute bioavailability of 43% (range 30-60%; Table 6a) . 13, 15, 140 Food has minimal effect on the bioavailability of telmisartan. 13, 15 It is highly bound (Ͼ99%) to plasma proteins. 13, 15, 141 Telmisartan has a very high Vd (approximately 500 L). 15 Plasma elimination t . of telmisartan is about 24 h (range 21-38 h), and Cl T is Ͼ800 mL/min (Table 6b) . 13, 15, 58, 142 The pharmacokinetics of telmisartan are nonlinear over the dose range of 20-160 mg, with greater than proportional increases in plasma levels with increasing doses. 15 Upon repeated dosing, telmisartan accumulates in plasma (150-200%) . 15 The drug is not metabolised by cytochrome P450 system, 13, 15, 143 and almost all of the oral dose is excreted unchanged in faeces (Table 7) , mainly by the biliary route. 13, 15, 143 A small amount of a glucuronide (11%) of telmisartan is found in the circulation. 15 Valsartan: When given as a capsule, 19-23% of the dose of valsartan is absorbed. 8, 14, 15, 144, 145 Oral bioavailability (Table 6a) is about 19% (range 10-35%) if given as a capsule, but 39-51% if given as a solution. 8, 14, 15, 145, 146 The T max of valsartan is 2-4 h after the administration of a capsule; 8, 14, 15 the absorption is more rapid if the drug is given as a solution (T max = 1 h). 145 Food decreases C max by 50% and AUC by 40%. 14, 15 The C max and AUC increase linearly with increasing dose (range 80-320 mg). 8 Protein binding of valsartan is high (94 -97%, mainly to albumin), 14, 15, 147 and its Vd is 17 L. 14, 15, 145 The Cl T of valsartan is 37 mL/min (Table 6b) , and plasma elimination t . is in the range of 6-10 h. 14, 15, [144] [145] [146] 148 The drug does not accumulate significantly (Ͻ20%) after repeated dosing. 8, 14, 15 Valsartan is eliminated mainly by biliary excretion as unchanged drug in faeces (Table 7; 80-85%) . 8, 14, 15, 148 Urinary excretion (mainly unchanged drug) accounts for 7%, 13% and 29% of the dose given as a capsule, as a solution or intravenously, respectively. 145, 148 Valsartan is not metabolised by the cytochrome P450 enzymes, 14, 15 but is converted to inactive compounds (15-20% of the dose), 14, 15, 145 with only 9% in the circulation.
146,148
Pharmacokinetics of angiotensin receptor blockers in special populations ( 14,15 But, female subjects were found to have twice as high C max for losartan 14, 15 and telmisartan 15 as in males; the AUC of telmisartan is also higher (250%) in females than in males. 15 However, these differences do not require adjustment of doses in female patients. 15 Elderly patients have higher AUC and C max of candesartan (by 50% and 80%, respectively), compared to young subjects, however, no initial dosage adjustment has been recommended based on age. 12, 14, 15 In mild to moderate renal insufficiency, higher serum levels of the drug are observed, and in severe disease, C max and AUC are increased two-fold.
14, 15 The drug is not removed by haemodialysis. 14, 15 In mild
Journal of Human Hypertension
to moderate hepatic disease, the changes in the pharmacokinetics are minor. 14, 15, 109, 117 No dosage adjustment is needed in mild to moderate renal or hepatic disease. 14, 15, 117 The elderly have about two-fold higher C max and AUC (for both total and unbound eprosartan in plasma) compared to young (most likely due to increased bioavailability of the drug in the elderly); 149 the T max is also higher (by 2.5 h) in the elderly. 119, 149 However, no initial dosage adjustment is necessary in the elderly. 119, 149 Hypertension has no effect on the pharmacokinetics of eprosartan. 119 In subjects with severe renal impairment, higher C max (by 35%) and AUC (by 55%) are found, and a decrease in Cl T by 95%, 119, 120 however, dosage adjustment is not necessary in patients with renal impairment. 119, 120 Hepatic disease causes an increase in AUC (40%), 123 and it is recommended to individualise the dose of eprosartan, based on tolerability and response, in patients with liver disease. 123 Ethnic differences have been noted in the pharmacokinetic parameters of irbesartan: compared to Whites, Blacks have a higher AUC (25%; NS, P = 0.11), C max , and plasma trough levels, and t . (20%) of irbesartan. 14, 15, 151 The elderly patients have higher AUC (20-43%) and C max (50%) of the drug than young patients, but the t . is not changed. 14, 15, 150 The renal clearance of irbesartan is decreased in elderly females. 150 However, these changes are not clinically significant and no dosage adjustment is recommended based on ethnicity, gender or age. 6, 14, 15, 27, 32, 150 Mild-to-moderate renal insufficiency does not influence the pharmacokinetics of irbesartan, 14, 15, 27, 152, 153 and significant drug accumulation does not occur. 153 Irbesartan is not cleared by haemodialysis. 14, 15, 153 Based on pharmacokinetic data, the starting dose need not be adjusted in subjects with mild-to-severe renal impairment or in patients undergoing haemodialysis. 14, 15, 152, 153 However, dose adjustment may be necessary in volumeor salt-depleted patients. 153 No significant differences were found in the pharmacokinetic parameters of irbesartan in patients with hepatic insufficiency and healthy subjects, 61, 152 hence, no dosage adjustment is necessary in these patients. 14, 15, 61, 152 Aging does not influence the pharmacokinetics of losartan. 14, 15 Rare cases of poor metabolisers of losartan (who convert only 1% of the dose of losartan to EXP3174) have been have been reported. 14, 15, 154 In these individuals, plasma EXP3174 levels are very low and the t . is long. 155 The pharmacokinetics of losartan or its active metabolite EXP3174 in patients with heart failure are similar to those in healthy subjects, and hence no dosage adjustment is needed in these patients. 133 In patients with severe renal disease, the AUC and t . of losartan increase by 50%; but these parameters are not affected for EXP3174. 14, 15 Renal excretion of both losartan and EXP3174 decrease significantly. 137 Neither losartan nor EXP3174 are removed by haemodialysis. 14, 15 No dosage adjustment is needed in patients with renal impairment, unless they are also volumedepleted. 9, 14, 15 The pharmacokinetics of losartan are altered in hepatic disease. In patients with mild to moderate liver cirrhosis, plasma levels of losartan and EXP3174 are five-and 1.7-fold higher, respectively, than in normal controls. 14, 15 Compared to normal subjects, patients with liver disease have a twofold higher oral bioavailability and 50% lower Cl T of losartan. 14, 15 Based upon pharmacokinetic data, a lower starting dose of losartan is recommended in patients with hepatic impairment. 14, 15 The pharmacokinetic parameters of telmisartan do not change with age, hence, adjustment of doses of telmisartan are not needed in the elderly patients. 13, 15 Mild to moderate renal insufficiency does not influence pharmacokinetics of telmisartan. 13, 15 The drug is not removed by haemodialysis. 15 In patients with hepatic disease, plasma concentrations increase as a result of increased bioavailability. 15 Telmisartan should be avoided or used with caution in patients with severe renal impairment, renal artery stenosis, impaired hepatic function, severe congestive heart failure, and in volume-and/or salt-depleted patients, since doses lower than 40 mg are not available. 13, 15 Valsartan pharmacokinetics is altered in the elderly patients; the AUC increases by 70% and t . is prolonged by 35%, 8, 14, 15 however, no dosage adjustment is necessary. 8, 14, 15 The pharmacokinetics of valsartan is not related to the degree of renal impairment, hence no dosage adjustment is recommended for mild to moderate renal insufficiency. 8, 14, 15 However, pharmacokinetic data are not available to make recommendations in patients with severe renal impairment. The drug is not removed by haemodialysis. 14, 15 In patients with mild to moderate hepatic disease, a two-fold increase in AUC is observed and the t . is prolonged, 14, 15, 156 but, no dosage adjustment is needed in such patients. 14, 15 No pharmacokinetic data are available in patients with severe hepatic diseases. (Table 9) No significant drug interactions occur when candesartan cilexetil is co-administered with glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, oral contraceptives. 14, 15 Since candesartan is not metabolised by the cytochrome P450 system and it has no effect on these enzymes, inhibitors and inducers of the P450 enzymes are not expected to interact with candesartan. 14, 15 Eprosartan has no clinically significant effect on the pharmacokinetics of digoxin 157 or the coagulation parameters of warfarin. 158 Similarly, eprosartan has no effect on glucose profile in non-insulindependent diabetic patients stabilized on glyburide. 159 Hence, no dosage adjustment of warfarin, digoxin or glyburide is necessary if co-administered with eprosartan.
Interactions of angiotensin receptor blockers with other drugs
Since eprosartan is not metabolised by cytochrome P450 system, it has a low potential for interaction with drugs which inhibit or are substrates for this enzyme system. 11 For example, fluconazole 124 or ranitidine 160 do not have a significant effect on the pharmacokinetics of eprosartan.
Administration of hydrochlorothiazide to hypertensive patients 14, 15, 128 or nifedipine to normal volunteers 14, 15, 161 has no effect on the pharmacokinetics of irbesartan. Irbesartan does not alter the pharmacodynamics or pharmacokinetics of warfarin, 14, 15, 162 or digoxin. 14, 15, 27 hence no dosage adjustment of warfarin or digoxin is necessary. 27 Fluconazole, at a dose of 200 mg/day, significantly increases the AUC (63%) and C max (19%) of irbesartan without affecting the T max ; 129 dosage adjustment may be needed if the two drugs are co-prescribed.
Losartan does not alter the pharmacokinetics of digoxin 163 or pharmacokinetics and pharmacodyn-S81 amics of warfarin, 164 hence, no dosage adjustment of digoxin or warfarin are needed. There is no clinically significant pharmacokinetic interaction between losartan and hydrochlorothiazide in hypertensive patients. 165 Inhibitors of drugs metabolised by the cytochrome P450 system have variable effects on the pharmacokinetics of losartan. For example, erythromycin, 136 ketoconazole, 166 or fluvastatin 167 do not have any significant effect on the steady-state pharmacokinetics of losartan and EXP3174. Cimetidine does not cause a significant change in the pharmacokinetics (18% increase in AUC) or pharmacodynamics of losartan. 168 On the other hand, grapefruit juice (an inhibitor of dug metabolism) increases the AUC of losartan (by 14%), and decreases the AUC of EXP3174 (by 19%), 169 while fluconazole, decrease the conversion of losartan to EXP-3174. 124, 170 Among the inducers of drug metabolism, phenobarbital 171 has minimal effect on the pharmacokinetics (20% increase in the AUC) of losartan or EXP3174. However, both rifampin and phenytoin alter the pharmacokinetics of losartan. Rifampin increases the clearance of both losartan and EXP3174 (decrease in AUC and t . , and increase in oral Cl T ). 136 Phenytoin increases the AUC of losartan by 66% and decreases the Cl T by 32% (due to competitive inhibition of metabolism of losartan to EXP3174); it also decreases the AUC of the metabolite by 64% (by simultaneous induction of the metabolism of EXP3174); 172 the t . of losartan is not altered.
Thus, pharmacokinetic interactions of losartan with certain inducers and inhibitors of cytochrome P450 enzymes may be clinically significant.
There are no clinically significant drug interactions of telmisartan with warfarin, acetaminophen, amlodipine, glibenclamide, ibuprofen and hydrochlorothiazide. 13, 15 Warfarin has no effect on the pharmacokinetic parameters of telmisartan. 13, 15, 173 Telmisartan reduces the trough plasma levels of warfarin, but without affecting coagulation parameters. 13, 15, 173 Since telmisartan causes variable increases in serum digoxin levels, digoxin levels should be monitored in patients taking this drug combination. 15 As telmisartan is not metabolised by cytochrome P450 enzymes and it has no effect on the activities of cytochrome P450 enzymes, it is not expected to interact with drugs metabolised by these enzymes. 15 
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There are no pharmacokinetic interactions of valsartan with amlodipine, atenolol, digoxin, furosemide, glyburide, hydrochlorothiazide, indomethacin and warfarin. 14, 15, 174 Cimetidine increases the C max of valsartan (due to enhanced absorption) by 51%, but the increase has no clinical significance; valsartan has no effect on the pharmacokinetics of cimetidine. 14, 15, 144 Pharmacokinetic differences among the angiotensin receptor blockers (1) Most of the antihypertensive activity of candesartan cilexetil and losartan is due to the metabolites, while eprosartan, irbesartan, telmisartan and valsartan are inherently active. (2) The systemic bioavailability varies widely among the ARBs, from a low of 10% for valsartan to as high as 80% for irbesartan. 
Conclusions
The angiotensin II receptor blockers (ARBs) represent a relatively new class of effective and well tolerated, orally active antihypertensive agents. The beneficial effects of therapy with the ARBs go beyond blood pressure control. Although, the ARBs share the same mechanism of action, their pharmacodynamic and pharmacokinetic profiles vary from compound to compound. The ARBs may prove to have beneficial haemodynamic and neurohormonal
